EBR Systems, Inc. · ASX:EBR
EBR Systems — Corporate Update (October 2022)
6 slides from EBR Systems's corporate update, Oct 21, 2022
Slide 1: WiSE Device Update
For personal use only WiSE® Device Update October 2022 1
Slide 2: Background
Background EBR has identified a potential increased rate of battery depletion in some WiSE® systems For personal use only WiSE® transmitter update Solution No impact to SOLVE trial • Ongoing technical assessments have ü EBR is working closely with clinical sites ü Does not affect timing of headline
Slide 3: Pivotal SOLVE trial unaffected
Pivotal SOLVE trial unaffected EBR does not expect this development to impact the timing or data of headline results for the SOLVE trial For personal use only Interim enrolment completed Timing and results unaffected COMPLETED COMPLETED1 H1 2023 - Headline results EBR does not expect this issue to i
Slide 4: Funding and operations
Funding and operations EBR has sufficient capital to support the company through to FDA approval and commercialisation For personal use only Strong cash position Defined operational pathway Commercialisation ü EBR remains well funded with US$79.3m ü Solution identified with implementation to ü EBR i
Slide 5: Advantages of WiSE
Advantages of WiSE® WiSE® addresses the shortcomings of traditional For personal use only pacemakers Wireless Eliminates lead complications such as placement difficulty, blood clots, unintended nerve stimulation, dislodgement, extraction and repositioning. Endocardial Delivers pacing directly to the
Slide 6: Disclaimer
Disclaimer The material contained in this document is a presentation of general information about may differ materially from what is expressed in this presentation. For personal use only the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the d